Maxx Chatsko

Maxx Chatsko

TMFBlacknGold

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles


Is AnaptysBio a Buy?

Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.



Is Incyte a Buy?

The company is a one-trick pony, but should generate profits for the foreseeable future. Can the pipeline finally come through for investors?


Is Amicus Therapeutics a Buy?

The gene therapy stock is trading at its lowest level in over two years. It recently announced preliminary third-quarter 2019 operating results.


Is Aerie Pharmaceuticals a Buy?

The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.






3 Things Repligen Investors Need to Watch

The year may be drawing to a close, but this biomanufacturing stock -- and any investor interested in it -- has plenty to look forward to.